Pharmacological Treatment of Presbyopia

Last updated: October 1, 2022
Sponsor: Shahid Beheshti University of Medical Sciences
Overall Status: Active - Recruiting

Phase

1

Condition

Presbyopia

Treatment

N/A

Clinical Study ID

NCT05564832
IR.SBMU.ORC.REC.1401.005
  • Ages 40-60
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

In this clinical trial, a total of 75 presbyopic patients in the age range of 40 to 60 years old will be participated. The right eyes of 45 patients will be treated by Biocarpine® and they will be considered as the case group, their left eyes will be defined as the controls. In another case group, the right eyes of 30 patients will received Vuity® eye drops and their left eyes will be considered as controls.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subjects with the best corrected visual acuity (BCVA) better than 0.3LogMAR
  • Patients with the symptom of blurred vision at near distance

Exclusion

Exclusion Criteria: Patients with amblyopia, cataract, corneal opacity, glaucoma, intraocular surgery, eyetroma, congenital pupil anomalies and those with the history of headache and allergy to theeye drop will be excluded from the study.

Study Design

Total Participants: 75
Study Start date:
August 01, 2022
Estimated Completion Date:
January 01, 2023

Connect with a study center

  • Hamideh Sabbaghi

    Tehran,
    Iran, Islamic Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.